Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).
Inclusion Criteria: * Patients must have pathologically or cytologically confirmed adenoid cystic carcinoma. Cancers arising from non-salivary gland primary sites are allowed. * Patients must have recurrent and/or metastatic disease not amenable to other curative intent therapy. * At least 4 weeks must have elapsed since the end of prior systemic treatment and/or 2 weeks since completion of radiotherapy with resolution of all treatment related toxicity to NCI CTCAE Version 5.0 grade \<1 (or tolerable grade 2) or back to baseline (except for alopecia, lymphopenia, or hypothyroidism) prior to s…
intravenously on Days 1, 8 and 15 of a 28-day cycle-dose can be done up to +/-3 days after the scheduled day of administration